{"filings":[{"id":99874,"accession_number":"0000009326-26-000016","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q1 net sales $270.7M (+8.1%); adjusted EBITDA $74.3M (+12.1%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $270.7M, up 8.1% YoY; GAAP EPS $1.25, adjusted EPS $1.33.","Adjusted EBITDA $74.3M (+12.1%); free cash flow $33.8M; operating cash flow $40.1M.","All three segments posted sales and earnings growth; record Q1 net sales, EBITDA, and net earnings.","New clinical fMRI study on VitaCholine suggests cognitive health benefits in post-menopausal women.","CEO cites strong business model resilience; no guidance change despite geopolitical and trade uncertainty."],"consensus_eps_estimate":null,"consensus_eps_actual":1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":270709000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116150,"accession_number":"0000009326-26-000004","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem reports record Q4 net sales $263.6M, adjusted EPS $1.31; full year revenue tops $1B for first time","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $263.6M (+9.8% YoY); GAAP EPS $1.21 vs $1.03; adjusted EPS $1.31 vs $1.13.","Full year revenue $1.037B (record, +8.8%); GAAP net earnings $154.8M (+20.5%); adjusted EBITDA $274.9M (+9.8%).","Record free cash flow $173.6M; CEO cites double-digit dividend increase for 2025.","All three segments delivered sales and earnings growth in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":4.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":1037161000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116149,"accession_number":"0001140361-26-006184","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Balchem appoints Erin L. Gilson as CAO effective April 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William A. Backus, VP and Chief Accounting Officer, retiring on March 31, 2026.","Erin L. Gilson elected VP and Chief Accounting Officer, effective April 1, 2026.","Gilson joined Balchem in February 2016; currently Senior Director, Accounting and Financial Reporting.","No material changes to Gilson's compensatory arrangement as a result of the election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132591,"accession_number":"0001140361-25-045137","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Balchem declares $0.96 annual dividend (10.3% increase), authorizes repurchase of up to 4M shares","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.96 per share declared on Dec 9, 2025, payable Jan 20, 2026 to holders of record Dec 23, 2025.","10.3% increase over prior year annual dividend, marking the 17th consecutive annual increase.","New stock repurchase program authorizes up to 4 million shares, replacing prior program with no expiration date.","Repurchases may be made in open market or private transactions at management's discretion, with no obligation to acquire any specific amount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132590,"accession_number":"0000009326-25-000019","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q3 2025: record sales $267.6M, adj. EPS $1.35, all segments grow","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record net sales $267.6M (+11.5% YoY); GAAP EPS $1.24 vs $1.03; adjusted EPS $1.35 vs $1.13.","Record adjusted EBITDA $71.4M (+11.0% YoY); free cash flow $50.7M.","All three segments achieved sales and earnings growth; new NY microencapsulation plant to double capacity.","Net debt reduced to $88.9M, leverage 0.3x; repaid $36M on revolver during Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":3.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":773544000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149122,"accession_number":"0000009326-25-000012","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q2 2025: record net sales $255.5M, adj. EPS $1.27 beat","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $255.5M, +9.1% YoY; GAAP EPS $1.17 vs $0.98 prior year quarter.","Record adjusted EBITDA $69.2M (+11.2%); adjusted EPS $1.27 vs $1.09.","All three segments grew; record sales and earnings in Human Nutrition & Health and Specialty Products.","Plans new $36M micro-encapsulation facility in Orange County, NY, pending county approval.","EU imposes provisional anti-dumping duties of 95.4%-120.8% on Chinese choline chloride imports effective July 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":2.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":505986000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168118,"accession_number":"0001140361-25-023176","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Balchem shareholders elect three Class 1 directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Theodore L. Harris elected with 24.96M votes for; 1.26M against; 963k abstain; 2.20M broker non-votes.","Monica Vicente elected with 26.45M for; 718k against; 18k abstain; 2.20M broker non-votes.","Matthew Wineinger elected with 26.13M for; 1.04M against; 19k abstain; 2.20M broker non-votes.","RSM US LLP ratified as auditor for FY2025: 28.86M for, 522k against, 8k abstain.","Advisory approval of executive compensation passed: 25.45M for, 1.69M against, 49k abstain; 2.20M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168117,"accession_number":"0001628280-25-019487","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q1 net sales $250.5M record; adj. EPS $1.22 vs $1.03 YoY; all segments grow","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales of $250.5M, up 4.5% YoY; GAAP EPS $1.13 vs $0.89; adjusted EPS $1.22 vs $1.03.","Record adjusted EBITDA of $66.3M, up 8.9% YoY; net earnings $37.1M, up 27.8%.","All three segments (Human Nutrition, Animal Nutrition, Specialty Products) posted sales and earnings growth.","Operating cash flow $36.5M; free cash flow $31.0M in Q1 2025.","Launched new corporate website and product brand sites; released 2024 Sustainability Report on April 22."],"consensus_eps_estimate":null,"consensus_eps_actual":1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":250519000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185325,"accession_number":"0001140361-25-006756","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Balchem CAO William A. Backus to retire on March 31, 2026; successor not yet named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William A. Backus, Vice President and Chief Accounting Officer, notified of retirement effective March 31, 2026.","No material changes to Backus' compensatory arrangement as a result of planned retirement.","Successor will be announced at a later date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185324,"accession_number":"0001628280-25-006975","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q4 record net sales $240M, adjusted EBITDA $62.8M, EPS $1.03","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales record $240.0M (+4.9% YoY); GAAP EPS $1.03 vs $0.82; adjusted EPS $1.13 vs $0.95.","Q4 adjusted EBITDA record $62.8M (+13.4%); free cash flow $39.8M.","Full-year record net sales $953.7M (+3.4%); GAAP EPS $3.93 vs $3.35; adjusted EPS $4.37 vs $4.00.","Full-year adjusted EBITDA record $250.3M (+8.4%); operating cash flow $182.0M.","Dividend increased double-digits; debt reduced by $119.6M in FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":3.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":953684000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185323,"accession_number":"0001140361-25-004806","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Balchem adopts executive severance policy and enhances deferred comp match for officers","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["New Executive Severance Policy provides cash severance (multiple of salary plus target bonus) and COBRA for termination without Cause or Involuntary Termination within Change in Control (CIC) Period.","Outside CIC: cash paid in installments over Severance Period; equity treated per award terms. Within CIC: equity accelerates fully (time-based) and performance at target.","Company will match executive contributions to deferred compensation plan up to 6% of base salary, matching the 401(k) plan percentage.","Severance conditioned on signing a separation agreement with restrictive covenants including non-compete and non-solicit.","Policy effective February 12, 2025; Committee retains authority to interpret and amend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201906,"accession_number":"0001140361-24-048915","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Balchem declares $0.87 dividend, 10.1% increase; payable Jan 17, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly dividend set at $0.87 per share, a 10.1% increase versus prior year.","Payable January 17, 2025 to holders of record December 26, 2024.","This marks the 16th consecutive annual dividend increase.","CEO Ted Harris cites strong financial performance and Board confidence in long-term strategies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201905,"accession_number":"0001628280-24-043760","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q3 net sales up 4.3% to $239.9M; record adjusted EBITDA $64.4M, up 7.6% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $1.03 versus $0.90 prior year; adjusted EPS record $1.13 versus $1.04.","Human Nutrition & Health and Specialty Products segments drove strong sales and earnings growth.","Cash from operations $51.3M; free cash flow $42.2M; repaid $39.6M revolving debt, net debt $153.3M (0.6x leverage).","Launched K2Vital Delta Fermented, VitaCholine Pro-Flo, and AminoShure-XL during the quarter.","Year-to-date 2024 net earnings $94.9M vs $81.9M; net sales $713.7M vs $693.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":713680000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201904,"accession_number":"0001140361-24-043626","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Joyce Lee resigns from Balchem board following planned employment change","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joyce Lee resigned as director on Oct 16, 2024, due to planned change in principal employment.","Board accepted resignation; served for five years.","No replacement announced; Board expressed appreciation for service.","Resignation under corporate governance guidelines for employment change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217946,"accession_number":"0001140361-24-041566","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Balchem reclasses four directors to balance board classes; adopts MGCL 3-804(c) vacancy-filling provision","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors Knutson, Lee, Vicente, and Fish moved among Class 1, 2, and 3 to approximate one-third per class, effective Sept 20, 2024.","Board now has three Class 1 (term exp. 2025), two Class 2 (2027), three Class 3 (2026) directors.","Board adopted resolution to be subject to MGCL 3-804(c); vacancies may be filled only by majority of remaining directors.","Articles Supplementary filed with Maryland SDAT on Sept 19, 2024, reflecting the election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217945,"accession_number":"0001628280-24-033055","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q2 net sales $234.1M (+1.2% YoY); record adjusted EBITDA $62.3M (+5.0%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.98 vs $0.93; adjusted EPS $1.09 vs $1.06.","Record adjusted EBITDA $62.3M (+5.0% YoY); cash from ops $45.0M; free cash flow $38.4M.","Human Nutrition & Health and Specialty Products segments post strong sales and earnings growth.","Launched Optifolin+ patented choline-enriched folate ingredient on May 20, 2024.","Repaid $35M revolving debt; net debt $202.8M; leverage ratio 0.9x."],"consensus_eps_estimate":null,"consensus_eps_actual":1.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":473740000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237877,"accession_number":"0001140361-24-031096","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Balchem shareholders elect four Class 2 directors and ratify RSM US LLP as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Daniel Knutson, Joyce Lee, Olivier Rigaud, Monica Vicente elected as Class 2 directors (2027 term).","Joyce Lee received 23,968,891 votes for vs 3,987,153 against; others passed with >85% support.","Appointment of RSM US LLP ratified with 28,981,040 votes for, 536,045 against.","Say-on-pay advisory approved with 27,117,930 votes for (96.9% of shares voted).","All results from June 20, 2024 Annual Meeting; broker non-votes reported for director election and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237876,"accession_number":"0001628280-24-020128","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem reports record Q1 net sales of $239.7M, adjusted EBITDA up 8%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $239.7M (+3.1% YoY), adjusted EBITDA $60.9M (+8.0% YoY), both all-time records.","GAAP EPS $0.89 vs $0.70; adjusted EPS $1.03 vs $0.94 in prior-year quarter.","Human Nutrition & Health segment sales $152.7M (+15.1%), earnings $33.3M (+80.4%).","Cash from operations $33.4M; free cash flow $26.8M for Q1 2024.","VitaCholine became Proud Partner of New York Jets, first sponsorship in nutritional ingredient category."],"consensus_eps_estimate":null,"consensus_eps_actual":0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":239659000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}